Breaking records and setting new benchmarks! Aurobindo Pharma’s Q2 results reveal an 85% surge in net profit to Rs 757 crore. Explore the financial extravaganza, from revenue spikes to a 300% interim dividend. Pharma’s rockstar is on the rise!
In the world of pharmaceutical triumphs, Aurobindo Pharma is stealing the spotlight once again! Brace yourselves for some jaw-dropping numbers as the Indian pharma giant reported an astounding 85 percent year-on-year surge in consolidated net profit, soaring to a staggering Rs 757 crore for the July-September quarter of the current fiscal year.
Hold on to your seats, because that’s not all! The company had already set the stage for this financial spectacle by reporting a profit of Rs 410 crore in the same period last year. Talk about an encore performance!
But wait, there’s more to this blockbuster report. The revenue game is strong, with the numbers dancing to the tune of Rs 7,219.4 crore, marking a mind-blowing 25.7 percent increase from the year-ago quarter. Take that, financial expectations!
Even the experts at CNBC TV18 were left scratching their heads as Aurobindo Pharma outshone their estimates, with a whopping Rs 665 crore and Rs 6915 crore for the topline and bottomline, respectively. It’s safe to say that Aurobindo Pharma just raised the bar for the whole industry.
Let’s break down the numbers further – the earnings before interest, taxes, depreciation, and amortization (EBITDA) climbed to Rs 1373.5 crore, up from Rs 791 crore in the year-ago period. The EBITDA margin? Hold onto your calculators, folks, it’s a staggering 19 percent, a significant jump from the 13.6 percent in the year-ago period.
Now, let’s take a tour around the globe of Aurobindo Pharma’s revenue streams. The US formulations (excluding Puerto Rico) revenue took center stage with a 35.7 percent year-on-year increase, reaching Rs 3,385 crore. Europe formulations revenue followed suit with a 16.7 percent YoY increase, hitting Rs 1,769 crore. And the Growth markets revenue? Not to be left behind, it increased by 24.7 percent YoY, making it a cool Rs 564 crore.
But that’s not the end of this financial rollercoaster! Aurobindo Pharma flexed its muscles in Research & Development (R&D), spending a hefty Rs 300 crore, which translates to 4.2 percent of revenues in the quarter. Not only that, the company filed 10 Abbreviated New Drug Application (ANDAs) with USFDA during the quarter and snagged final approval for 15 ANDAs, including 3 injectable products.
The cherry on top? The Anti Retro Viral business revenue soared by an impressive 52.1 percent YoY to Rs 250 crore, accounting for 3.5 percent of consolidated revenue. Meanwhile, the Active Pharmaceutical Ingredient business revenue increased by 20.3 percent, reaching Rs 1,166 crore and contributing 16.2 percent of consolidated revenue.
And if you thought that’s the end, Aurobindo Pharma is spreading the joy by announcing a first interim dividend of 300 percent, i.e., Rs.3.00 per equity share of Rs 1/- each on the equity share capital of the Company. Cue the applause!
In a press statement, K. Nithyananda Reddy, Vice-Chairman, and Managing Director, exclaimed, “This is yet another quarter with the highest ever sales, driven by robust performance across the markets, and continued margin expansion, aided by operational leverage and efficiencies. With our strong product pipeline, focus on compliance, and key projects in advanced stages, we will continue our growth journey, while generating value for our stakeholders.”
So, there you have it – Aurobindo Pharma is not just a player; it’s the rockstar of the pharmaceutical world, and the Q2 results are the concert that everyone’s talking about! Stay tuned for more financial fireworks from this industry game-changer. For more updates like this stay tuned with us.
